About
I am a Research Director (DR2) at INSERM.
I received my PhD degree in human genetics in 2000 and then joined the team of V. Pachnis (NIMR, London) to work on the function of the SOX10 transcription factor and the endothelin-3 molecule during enteric nervous system development in mouse.
In 2003, I was appointed as a Research scientist at INSERM and joined the team of M. Goossens within the Institut Mondor de Recherche Biomedicale (IMRB, Creteil) to work on cellular and molecular bases of Waardenburg syndrome type 4.
Research Director since 2013, I pursue my projects with specific interest in transcriptional and post-transcriptional control during NC development, with focus on enteric, Schwann cells and melanocytes.
In 2016, our group moved to the Imagine Institute to join the team headed by J. Amiel, to address both basic and medical research related to the neural crest.
Scientific project
Over the past 30 years, our research projects focused on neural crest development and related pathologies, integrating human, mouse molecular genetics and developmental biology.
Our group has been at the heart of genetic studies highlighting involvement of SOX10 in various neurocristopathies (Waardenburg syndrome type 2, isolated Hirschsprung disease and Kallmann syndrome). Making use of both mouse and in vitro culture systems, our group also characterized several of the genetic interactions taking place between SOX10 and key genes during enteric nervous system development.
More recently, we extended our area of research to post-transcriptional mechanisms controlling neural crest development with a particular interest in A to I RNA editing role in Schwann cell development and myelin maintenance.
The "neurocristopathies" theme includes:
- Molecular and cellular bases of neurocristopathies: focus on Hirschsprung disease and Waardenburg syndrome (PI V. Pingault and N. Bondurand)
- Transcriptional and post-transcriptional control of neural crest development with focus on enteric nervous system and Schwann cells (PI N. Bondurand)
2021Journal (source)J Clin Invest